Aravive is a clinical-stage biotechnology company developing therapies for solid tumors and hematologic malignancies. It develops AVB-S6-500, a GAS6 binding protein and AXL decoy receptor for the treatment of ovarian cancer, renal cell carcinoma, acute myeloid leukemia, triple-negative breast cancer, and pancreatic cancer. The company was formed as a result of a merger between Versartis and Aravive Biologics.